Greg D. Perry

Gregory Perry is the current director at Merus. Prior to their current position, Perry served as the chief financial officer at Finch Therapeutics Group from May 2018 to April 2022. Gregory also held the position of chief financial & administrative officer at Novelion Therapeutics from December 2016 to December 2017.

Perry has over 20 years of experience in the biopharmaceutical industry. Gregory has a proven track record in leading finance and operations for public and private companies. Perry has a deep understanding of the rare disease market and is passionate about developing new therapies to improve the lives of patients with rare diseases.

Gregory Perry's educational career includes a BA in Economics & Political Science from Amherst College.